Ralpancizumab
Ralpancizumab
Ralpancizumab (pronunciation: ral-pan-ciz-u-mab) is a monoclonal antibody designed for the treatment of various cancer types.
Etymology
The name "Ralpancizumab" is derived from the standard nomenclature for monoclonal antibodies. The suffix "-mab" indicates it is a monoclonal antibody, while the infix "-cizu-" suggests its cancer-related use.
Function
Ralpancizumab works by binding to specific proteins on the surface of cancer cells, inhibiting their growth and proliferation. This is achieved through the process of immunotherapy, a treatment method that uses the body's immune system to fight diseases such as cancer.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Immunotherapy: A type of cancer treatment that helps your immune system fight cancer.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
See Also
External links
- Medical encyclopedia article on Ralpancizumab
- Wikipedia's article - Ralpancizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski